Intelligence · Patents
Patents expiring in 2038
Annual patent cliff calendar for 2038 — US pharmaceutical patents by expiration date.
- Patents
- 1,509
Quick answer
1,509 indexed pharmaceutical patents have expiration dates in 2038. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10143671
Solid solution compositions and use in chronic inflammation
granted -
US 10143751
Photodynamic therapy, formulation usable for this purpose, and method for the production and use thereof
granted -
US 10144743
1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
granted -
US 10144753
Anthracycline derivatives for treating tumor diseases
granted -
US 10143636
Porous silica particle and cleansing cosmetic
granted -
US 10143660
Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
granted -
US 10143690
Oligomer-opioid agonist conjugates
granted -
US 10143702
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted -
US 10143709
Use of ASC and ASC-CM to treat ARDS, SARS, and MERS
granted -
US 10143721
Combination product for the prevention of sexually transmitted infections
granted -
US 10143724
Anti-SSX-2 T cell receptors and related materials and methods of use
granted -
US 10143748
B-cell reduction using CD37-specific and CD20-specific binding molecules
granted -
CA 3065417
TRAITEMENT DE MALADIES ASSOCIEES A UNE DYSREGULATION DE LA VOIE MTOR
granted -
US 10151763
Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
granted -
US 10149470
Methods and compositions for vein harvest and autografting
granted -
US 10149481
Arthropod control compositions and methods
granted -
US 10150948
Compositions and methods for producing and administering brown adipocytes
granted -
US 10150753
Salt forms and polymorphs of (R)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyrdin-2-yl)acetamido) pyridazin-3-yl)-2-fluorobutyl)-N-methyl-1H-1,2,3-triazole-4-carboxamide
granted -
US 10150788
Prodrug compounds and uses thereof
granted -
US 10150806
Aldehyde tags, uses thereof in site-specific protein modification
granted -
US 10149903
Fully human antibody against respiratory syncytical virus
granted -
US 10149897
Scaffolds for cell transplantation
granted -
US 10150783
Heterocyclic ITK inhibitors for treating inflammation and cancer
granted -
US 10149829
Treatment of circadian rhythm disorders
granted -
US 10150734
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
granted -
US 10149853
Stabilized formulations of CNS compounds
granted -
US 10149912
Dehydrated hydrogel inclusion complex
granted -
US 10149906
Targeting microbubbles
granted -
US 10149847
Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
granted -
US 10151756
Predictive markers for polyamine inhibitor cancer therapies
granted -
US 10149841
Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof
granted -
US 10149836
Isoxazole treatments for frontotemporal dementia
granted -
US 10149842
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 10154986
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10155003
Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
granted -
US 10155796
Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5
granted -
US 10155743
Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
granted -
US 10155016
Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
granted -
US 10155011
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
granted -
US 10154975
Solid solution compositions and use in chronic inflammation
granted -
US 10154970
Methods for immunomodulation of cancer and infectious disease therapy
granted -
US 10154669
Improving color and release profile of resin compositions comprising silver nanoparticles
granted -
US 10154681
Goitrogen-free beverage, methods of use and method of formulating the same
granted -
US 10154881
Methods and compositions for tissue adhesives
granted -
US 10154965
Osmotic drug delivery system
granted -
US 10154974
Use of abscisic acid for the prevention and treatment of malaria
granted -
US 10154982
Ketone bodies and ketone body esters as blood lipid lowering agents
granted -
US 10154992
Compounds and methods for treating HIV infection
granted
Frequently asked questions
How many pharma patents expire in 2038?
1,509 published patents in our USPTO index have expiration dates falling in calendar year 2038.